K2P Channel Modulation via Yeast-Based Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
K2P potassium channels, crucial for pain perception and neurological functions, lack specific pharmacology due to their 'leak' current nature, which complicates conventional electrophysiological screening and hinders the development of effective modulators.
Innovation Solution
A yeast-based high-throughput screening assay is developed to identify modulators of K2P channels, specifically targeting TREK-1 channels, using compounds like ML67-33 that selectively activate heat- and mechanosensitive channels by acting on the extracellular selectivity filter-based C-type gate, overcoming the challenges of conventional screening methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional electrophysiological screening assays are used to detect K2P channel modulators, then the screening process can identify potential drugs, but the 'leak' current nature of K2P channels makes detection difficult and reduces measurement precision
Solution Approach 1:
The patent uses an intermediary assay system (yeast-based or cell-based with fluorescent reporters) to detect K2P channel activity indirectly through potassium flux measurements, rather than directly measuring the elusive leak current through conventional electrophysiology. This intermediary approach converts the difficult-to-detect leak current into a measurable signal.
Solution Approach 2:
The patent replaces the mechanical/electrical measurement system of conventional electrophysiology with a biochemical/optical detection system using fluorescent reporters that change emission properties in response to potassium flux, thereby substituting direct electrical measurement with an optical readout that is more sensitive and easier to automate.
2Productivity
If K2P channels are targeted for therapeutic development, then new treatments for neurological disorders can be created, but the scarcity of facile detection methods and poor responsiveness to classic blockers hinders drug development
Solution Approach 1:
The patent segments the drug discovery process into distinct phases: first using the yeast-based assay for initial high-throughput screening to identify hits, then using cell-based assays for validation and characterization. This segmentation allows each assay type to be optimized for its specific purpose, improving overall productivity.
Solution Approach 2:
The patent changes the detection parameter from direct electrical current measurement to fluorescent signal intensity, which is more amenable to high-throughput screening formats. This parameter change enables automated detection and significantly increases screening capacity while maintaining sensitivity.
3Reliability
If specific K2P pharmacology is developed, then targeted therapies for pain and neurological disorders can be achieved, but the 'leak' current produces a background signal that challenges conventional screening assays
Solution Approach 1:
The patent extracts the detection of potassium flux from the complex background of leak current by using fluorescent reporters that specifically respond to potassium concentration changes. This extraction isolates the relevant signal from the noisy background, improving reliability of pharmacological targeting.
Solution Approach 2:
The patent creates a simplified copy of the K2P channel function in a controlled assay system using yeast or engineered cells with fluorescent reporters. This copy allows screening without the complexity of native mammalian cell electrophysiology, reducing assay complexity while maintaining pharmacological relevance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach facilitates the discovery of new K2P modulators, enabling both mechanistic and physiological testing of K2P activity and improving the pharmacological targeting of K2P channels, potentially leading to therapeutic interventions for neurological disorders.
Implementation Method 1
ML67-33, a low micromolar selective activator of heat- and mechanosensitive K2P channels that acts on the extracellular selectivity filter-based C-type gate
Data Source
AI summary
Disclosed herein inter alia are compositions and methods useful in the treatment of diseases, for example pain, neurodegeneration, or mood disorders, and for modulating the activity of a K2P channel.